The Torcetrapib project was terminated on December 2, 2006 due to safety findings.

Cholesterol levels will be measured over six weeks in subjects being treated with two different kinds of cholesterol medications to see how the different treatments compare to one another.

For additional information please call: 1-800-718-1021

Inclusion Criteria:

• eligible for statin treatment for LDL cholesterol by NCEP guidelines

Exclusion Criteria:

• Women who are pregnant or lactating, or planning to become pregnant.
• Subjects taking any drugs known to be associated with an increased risk of myositis in combination with HMG-CoA reductase inhibitors.
• Subjects with significant liver or kidney disease or significant heart failure.